AI Article Synopsis
Article Abstract
Background: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.
Methods: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective Influenza Resistance Information Study (IRIS, NCT00884117) were evaluated. Cultured viruses were phenotypically tested for neuraminidase inhibitor (NAI) sensitivity, and sequenced to determine virus lineage (B/Victoria or B/Yamagata). Differences in clinical outcomes (viral clearance and symptom resolution) between virus lineages were assessed using Kaplan-Meier analysis.
Results: In all, 914 patients were positive for influenza B by reverse transcriptase polymerase chain reaction (
Rt-pcr: B/Victoria, 586; B/Yamagata, 289; not subtyped, 39); 474 were treated with antivirals. No phenotypic resistance to oseltamivir or zanamivir was found in B/Victoria or B/Yamagata viruses. Of 15 predefined resistance mutations, 2 were detected by neuraminidase sequencing: I221T had reduced sensitivity to oseltamivir, and I221V was sensitive to NAI inhibition. No consistent differences between virus lineages in times to viral clearance or to symptom or fever resolution were found in adults and adolescents or in children.
Conclusions: Influenza B virus lineage had no notable effect on disease outcomes or antiviral susceptibility in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiv375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antigenic changes in influenza A(H3N2) driven by genetic evolution: Insights from virological surveillance, EU/EEA, week 40/2023 to week 9/2024.
Euro Surveill
December 2024
Members of the ERLI-Net who contributed virus detection and/or characterisation data or were involved in weekly surveillance activities are listed under Collaborators (affiliations at the end of the article).
BackgroundDuring the 2023/24 influenza season in the European Union/European Economic Area (EU/EEA), influenza viruses A(H1N1)pdm09, A(H3N2) and B/Victoria viruses were co-circulating.AimWe aimed to describe the circulating influenza viruses by (sub)type, genetic clade, antigenic group and antiviral susceptibility in that season in the EU/EEA.MethodsWe collected surveillance data from EU/EEA countries through weekly submissions to The European Surveillance System (TESSy).
View Article and Find Full Text PDFCross-neutralization of Influenza A by SARS-CoV-2 specific neutralizing antibodies and polyclonal plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A?
Heliyon
December 2024
Virology Laboratory, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, (icddr,b), Bangladesh.
According to sparse information from various countries, the seasonal influenza virus circulation has drastically decreased during the COVID-19 pandemic. Here, we show the cross-reactivity of anti-SARS-CoV-2 antibodies against influenza viruses. Plasma samples were collected from 311 SARS-CoV-2 infected individuals.
View Article and Find Full Text PDFSafety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
Lancet Infect Dis
November 2024
Moderna, Cambridge, MA, USA.
Background: Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who are at high risk for severe respiratory disease. The RSV mRNA-1345 vaccine demonstrated efficacy against RSV disease with acceptable safety in the ConquerRSV trial in adults aged 60 years and older. We aimed to evaluate the safety and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine or SARS-CoV-2 mRNA vaccine.
View Article and Find Full Text PDFImmunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls.
Vaccines (Basel)
October 2024
Vaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021-2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy ( = 33), HSCT ( = 27), and healthy controls ( = 20).
View Article and Find Full Text PDFImplications of the apparent extinction of B/Yamagata-lineage human influenza viruses.
NPJ Vaccines
November 2024
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute, Melbourne, VIC, Australia.
Following the onset of the COVID-19 pandemic in 2020, the number of influenza viruses circulating globally fell to historically low numbers. Although influenza A and B/Victoria lineage viruses returned to normal patterns by 2022, B/Yamagata-lineage viruses have not been identified since 2020. The implications of the apparent extinction of this lineage of viruses on vaccine composition, and the risk of their re-introduction into the human population are discussed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!